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osting by EAbstract A novel 3-(substituted benzylideneamino)-7-chloro-2-phenyl quinazoline-4(3H)-one
(7–27) has been synthesized and characterised by IR, 1H NMR, 13C NMR spectroscopy, and
elemental analysis. We changed the methodology for the synthesis of 3-amino 7-chloro-2-phenyl
quinazolin-4(3H)-one 6 to fusion reaction at 250 C, instead of using solvent, to avoid the problem
of ring opening, which is commonly observed while synthesizing quinazolines from benzoxazinone.
NCI selected, 7-chloro-3-{[(4-chlorophenyl) methylidene] amino}-2-phenylquinazolin-4(3H)-one
12, with GI50 value of 5.59 M, TGI value of 5.12 M, and LC50 value of 4.40 M showed
remarkable activity against CNS SNB-75 Cancer cell line. Rational approach and QSAR
techniques enabled the understanding of the pharmacophoric requirement for 2,3,7-tri substituted
quinazoline derivatives to inhibit EGFR-tyrosine kinase as antitumor agents and could be used as
an excellent framework in this ﬁeld that may lead to discovery of potent anti tumor agent.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.91 9417563874; fax: +91
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lsevier1. Introduction
Protein tyrosine kinases are enzymes involved in many cellular
processes such as cell proliferation, metabolism, survival, and
apoptosis. Several protein tyrosine kinases are known to be
activated in cancer cells and to drive tumor growth and pro-
gression. Blocking tyrosine kinase activity therefore represents
a rational approach to cancer therapy. Protein kinases (PTKs)
catalyze the phosphorylation of tyrosine and serine/threonine
residues in various proteins involved in the regulation of all
functions (Jordan et al., 2000). They can be broadly classiﬁed
as receptor such as EGFR, or non-receptor kinases. Inappro-
priate or uncontrolled activation of many of these kinases, by
Chart 1 EGFR-tyrosine kinase inhibitors.
Figure 1 Reported and proposed a
36 M.N. Noolvi, H.M. Patelover-expression, constitutive activation, or mutation, has been
shown to result in uncontrolled cell growth (Blume-Jensen and
Hunter, 2001). Overexpression of these receptors was found in
a number of cancers (e.g., breast, ovarian, colon, and prostate),
their expression levels often correlate with vascularity, and is
associated with poor prognosis in patients (Slichenmeyer
et al., 2001; Fricker, 2006). Inhibitors of the EGFR PTK are
therefore expected to have great therapeutic potential in the
treatment of malignant and nonmalignant epithelial diseases.
Drug discovery efforts have targeted this aberrant kinase
activity in cancer, asthma, psoriasis, and inﬂammation (Cohen,
2002). Recent advances in the identiﬁcation of erbB family
kinase inhibitors have created hope for the modulation of
uncontrolled cell growth in cancer therapy for solid tumors
(Gschwind et al., 2004).
This strongly suggests that these targets represent drug
intervention opportunities due to pivotal role in governing cel-
lular proliferation, survival, and metastasis. A great number of
different structural classes of tyrosine kinase inhibitors have
been reported and reviewed (Adams, 2001; Yarden andntitumor quinazoline derivatives.
Figure 2 Model of the ATP-binding site of protein kinases. ATP
is depicted in red; Sug1, Hyp1, and Hyc1 are residues lining the
sugar region, hydrophobic pocket (Hyp), hydrophobic channel
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molecule selective EGFR-TK inhibitors include quinazolines.
Chart 1 includes some examples that are currently approved
drugs or in clinical trials (Fricker, 2006).
In view of previous rational and in continuation of our re-
search for newer anti-cancer agents (Manjula et al., 2009;
Badiger et al., 2006) in the present study new series of 2,3,7-
tri substituted quinazoline have been optimized and synthe-
sized (Fig. 1). Quinazoline ring opening is a common phenom-
enon in the synthesis of quinazoline from benzoxazinone. We
changed the methodology for the synthesis of 3-amino 7-
chloro-2-phenyl quinazolin-4(3H)-one 6 to fusion reaction at
250 C, instead of using solvent, to avoid the problem of ring
opening, which is commonly observed while synthesizing quin-
azolines from benzoxazinone. By using this new methodology
the preparation of 3-amino 7-chloro-2-phenyl quinazolin-
4(3H)-one 6 is simple, time-saving and eco-friendly process
without solvent and also avoid the problem of ring opening.
Thus, it is a step towards green chemistry.
(Huc), and hinge region (Hin), respectively.2. Rational and design
In recent years, quinazolines have emerged as a versatile tem-
plate for inhibition of a diverse range of receptor tyrosine ki-
nases. The most widely studied of these is the epidermal
growth factor receptor (EGFR), with the small-molecule
inhibitor geﬁtinib being the ﬁrst agent from this class to be ap-
proved for the treatment of Non-Small Cell Lung Cancer
refractory to prior chemotherapeutic intervention (Peter
et al., 2006; Ranson, 2004). Subsequent research aimed at fur-
ther exploration of the SAR of this novel template has led to
discovery of highly selective compounds that target EGFR.
These compounds act via competing with ATP for binding
at the catalytic domain of tyrosine kinase. Later on, a great
structural variety of compounds of structurally diverse classes
have proved to be highly potent and selective ATP-competitive
inhibitors. The ATP binding site has the following features;
Adenine region – contains two key hydrogen bonds formed
by the interaction of N-1 and N-6 amino group of the adenine
ring. Many potent inhibitors use one of these hydrogen bonds.
Sugar region – a hydrophilic region, except a few e.g., EGFR.
Hydrophobic pocket – though not used by ATP but plays an
important role in inhibitor selectivity. Hydrophobic channels
– it is not used by ATP and may be exploited for inhibitor
speciﬁcity. Phosphate binding region – this is used for improv-
ing inhibitor selectivity (Fig. 2) (Fabbro et al., 2002). In this
study, we present a new sub-family of compounds containing
2,3,7-tri substituted quinazoline core as EGFR inhibitors.
Our strategy is directed toward designing a variety of ligands
with diverse chemical properties hypothesizing that the po-
tency of these molecules might be enhanced by adding alterna-
tive binding group such as phenyl ring at position 2-, imines at
position 3-, and chloro group at position 7- of the quinazoline
ring. In this way, such substitution pattern could target differ-
ent regions of the ATP-binding site of the protein kinase do-
main to create differentially selective molecules. The design
of our ligands was done based on previous quantitative struc-
ture–activity relationship (QSAR) of 4-anilinoquinazolines as
EGFR inhibitor (Noolvi and Patel, 2010, Noolvi et al.,
2011). We introduced larger moiety at 3 position of the quinaz-
oline such as substituted arylidene moiety in a fashion similarto lapatinib which binds in the ATP-binding cleft, so that the
bulky group could be oriented deep in the back of the ATP
binding site and makes predominantly hydrophobic interac-
tions with the protein mimicking the 30-chloro-40-[(3-ﬂuorob-
enzyl)oxy]aniline group of lapatinib (Fig. 3).
3. Materials and methods
3.1. Chemistry
4-Chloro 2-amino benzoic acid 1 reaction with benzoyl chloride
2 yielded 7-chloro 2-phenyl-4H-3, 1-benzoxazin-4 one 3 by N-
acylation via dehydrative cyclization mechanism. Subsequently
which was reﬂuxed with hydrazine hydrate in dry pyridine in an
attempt to obtain 3-amino 7-chloro-2-phenyl quinazolin-4(3H)-
one, but we got mixture of 3-amino 7-chloro-2-phenyl quinazo-
lin-4(3H)-one 5 and ring opened N-(5-chloro-2(hydrazine car-
bonyl) phenyl) benzamide 4. Later we tried the same reaction
at 250 C by fusion without any solvent and this time we got
the desired product 3-amino 7-chloro-2-phenyl quinazolin-
4(3H)-one 6 without any ring opened structure (diamides). Fu-
sion is more convenient and time saving method since it takes
only 0.5 h, where conventional takes 3.0 h for the reaction. On
the other hand ring opening is a common phenomenon in the
synthesis of quinazoline from benzoxazinone. This problem
can be avoided by fusing benzoxazinone at high temperature
resulting in the synthesis of desired quinazoline otherwise one
will get mixture of quinazoline and ring opened quinazoline
(diamides), as shown mechanistically in Chart 2. Condensation
of 6 with different substituted aromatic aldehydes gave corre-
sponding arylidene derivatives of quinazoline 7–27 in glacial
acetic acid (Scheme 1).
3.2. Anticancer screening at NIH, Bethesda, Maryland, USA
The tumor growth inhibition properties of compounds 12 with
the NCI codes NSC D-753447/1 selected among 7–27 synthe-
sized compounds (Scheme 1) by the National Cancer Institute
(NCI), USA, were screened on human tumor cell lines at the
NIH, Bethesda, Maryland, USA, under the drug discovery
program of the NCI, for one and ﬁve dose anti-cancer assay.
Figure 3 Proposed hypothetical model of the 2,3,7-trisubstituted quinazoline bound to ATP binding site of EGFR-protein tyrosine
kinase.
38 M.N. Noolvi, H.M. PatelThe screening is a two-stage process, beginning with the
evaluation of all compounds against the 60 cell lines at a single
dose of 10 lM. The output from the single dose screen is re-
ported as a mean graph and is available for analysis by the
COMPARE program. Compounds which exhibit signiﬁcant
growth inhibition are evaluated against the 60 cell panel at ﬁve
concentration levels. The human tumor cell lines of the cancer
screening panel are grown in RPMI 1640 medium containing
5% fetal bovine serum and 2 mM L-glutamine. For a typical
screening experiment, cells are inoculated into 96-well microti-
ter plates in 100 ll at plating densities ranging from 5000 to
40,000 cells/well depending on the doubling time of individual
cell lines. After cell inoculation, the microtiter plates are incu-
bated at 37 C, 5% CO2, 95% air, and 100% relative humidity
for 24 h prior to addition of experimental drugs.
After 24 h, two plates of each cell line are ﬁxed in situ with
TCA, to represent a measurement of the cell population for
each cell line at the time of drug addition (Tz). Experimental
drugs are solubilized in dimethyl sulfoxide at 400-fold the de-
sired ﬁnal maximum test concentration and stored frozen prior
to use. At the time of drug addition, an aliquot of frozen con-
centrate is thawed and diluted to twice the desired ﬁnal maxi-
mum test concentration with complete medium containing
50 lg/ml gentamicin. Additional four, 10-fold or ½ log serial
dilutions are made to provide a total of ﬁve drug concentra-
tions plus control. Aliquots of 100 ll of these different drug
dilutions are added to the appropriate microtiter wells already
containing 100 ll of medium, resulting in the required ﬁnal
drug concentrations.
Following drug addition, the plates are incubated for an
additional 48 h at 37 C, 5% CO2, 95% air, and 100% relativehumidity. For adherent cells, the assay is terminated by the
addition of cold TCA. Cells are ﬁxed in situ by the gentle addi-
tion of 50 ll of cold 50% (w/v) TCA (ﬁnal concentration, 10%
TCA) and incubated for 60 minutes at 4 C. The supernatant is
discarded, and the plates are washed ﬁve times with tap water
and air dried. Sulforhodamine B (SRB) solution (100 ll) at
0.4% (w/v) in 1% acetic acid is added to each well, and plates
are incubated for 10 minutes at room temperature. After stain-
ing, unbound dye is removed by washing ﬁve times with 1%
acetic acid and the plates are air dried. Bound stain is subse-
quently solubilized with 10 mM trizma base, and the absor-
bance is read on an automated plate reader at a wavelength
of 515 nm. For suspension cells, the methodology is the same
except that the assay is terminated by ﬁxing settled cells at
the bottom of the wells by gently adding 50 ll of 80% TCA (ﬁ-
nal concentration, 16% TCA). Using the seven absorbance
measurements [time zero, (Tz), control growth, (C), and test
growth in the presence of drug at the ﬁve concentration levels
(Ti)], the percentage growth is calculated at each of the drug
concentrations levels. Percentage growth inhibition is calcu-
lated as:
½ðTi TzÞ=ðC TzÞ  100 for concentrations for which Ti > = ¼ Tz
½ðTi TzÞ=Tz  100 for concentrations for which Ti < Tz
Three dose–response parameters are calculated for each
experimental agent. Growth inhibition of 50% (GI50) is cal-
culated from [(Ti  Tz)/(C  Tz)] · 100 = 50, which is the
drug concentration resulting in a 50% reduction in the net
protein increase (as measured by SRB staining) in control
cells during the drug incubation. The drug concentration
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Chart 2 Reaction mechanism and ring opening phenomenon in the synthesis of target compound 7–27 (Scheme 1).
Synthesis, method optimization, anticancer activity of 2,3,7-trisubstituted quinazoline derivatives 39resulting in total growth inhibition (TGI) is calculated from
Ti = Tz. The LC50 (concentration of drug resulting in a
50% reduction in the measured protein at the end of the drug
treatment as compared to that at the beginning) indicating a
net loss of cells following treatment is calculated from
[(Ti  Tz)/Tz] · 100 = 50. Values are calculated for each
of these three parameters if the level of activity is reached;
however, if the effect is not reached or is exceeded, the valuefor that parameter is expressed as greater or less than the
maximum or minimum concentration tested (Alley et al.,
1988; Grever et al., 1992; Boyd and Paul,1995).
4. Result and discussion
In the present work, 2,3,7-trisubstituted quinazolines were
prepared according to reaction Scheme 1. The spectral data
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Scheme 1 Synthetic route for the synthesis of quinazoline derivatives (7–27).
40 M.N. Noolvi, H.M. Patelof 7–27 showed IR band at 1634–1678 cm1 due to stretching
vibration of C‚O group of the quinazoline moiety and
absorption band at 1372–1436 cm1 is due to the C–N stretch-
ing vibration. C–Cl stretching vibration is appeared at 721–
768. Further 1H NMR of compounds 7–27 showed presence
of a singlet between d 8.77 and 9.34 ppm indicate the forma-
tion of imine (>HC‚N–). Peak at d 7.10–8.30 ppm showed
presence of aromatic protons. Synthesis of 7–27 compounds
was also conﬁrmed by 13C NMR data, peak at around d
168.23 ppm has conﬁrmed formation imine (>HC‚N–).
The tumor growth inhibition properties of compounds 12
with the NCI codes NSC D-753447/1 selected among 7–27 syn-thesized compounds (Scheme 1) by the National Cancer Insti-
tute (NCI), USA, were screened on human tumor cell lines at
the NIH, Bethesda, Maryland, USA, under the drug discovery
program of the NCI, for one and ﬁve dose anti-cancer assay.
The tested quinazoline derivative showed a distinctive pat-
tern of selectivity. With regard to sensitivity against individual
cell lines (Fig. 4), compound 12 showed remarkably lowest cell
growth promotion against Renal A-498 cancer cell line of
43.73, apart from this it also exhibited broad spectrum cell
growth inhibition against Non-Small Cell Lung Cancer NCI-
H522 (cell growth promotion 20.09%, inhibition 79.91%), Co-
lon cancer HCT-116 (cell growth promotion 38.26%,
Figure 4 One dose mean graph of compound 12 at 105 M concentration.
Synthesis, method optimization, anticancer activity of 2,3,7-trisubstituted quinazoline derivatives 41inhibition 61.74%), CNS cancer U-251 (cell growth promotion
37.22%, inhibition 62.78%), and Ovarian OVCAR-8 cell line
(cell growth promotion 33.54%, inhibition 66.46%) at concen-
tration of 105 M in one dose primary assay.
The same compound was further screened for 5-log dose
range as it has shown prominent cell growth inhibition at
105 M concentration against verity of cell lines. Three re-
sponse parameters, median growth inhibition (GI50), totalgrowth inhibition (TGI), and median lethal growth inhibition
(LC50) were calculated for each cell line (Skehan et al., 1990).
It showed remarkable activity against CNS SNB-75 cancer cell
line with GI50 value of 5.59 and TGI value of 5.12 apart
from this it also exhibited broad spectrum cell growth inhibi-
tion against: Non-Small Cell Lung Cancer Lines; HOP-62
(GI50 value 5.13 and TGI value 4.51), NCI-H226 (GI50 va-
lue 5.40 and TGI value 4.70), NCI-H23 (GI50 value 5.08
Table 1 National Cancer Institute developmental therapeutics program in-vitro testing results of compound 12.
NSC: D-753447/1 Experiment ID: 1009 NS13 Units: Molar
COMI: SIH6 (96135) Strain reagent: SRB Dual Pass SSPL: 0XXS
Parent cell line Time Mean optical densities Percent growth GI50 TGI LC50
Zero Control 8.0 7.0 6.0 5.0 4.0 8.0 7.0 6.0 5.0 4.0
Leukemia
CCRFCEM 0.356 1.727 1.680 1.633 1.696 1.628 1.559 97 93 98 93 88 >1.00 E4 >1.00 E4 >1.00 E4
MOLT-4 0.439 1.652 1.712 1.741 1.718 1.628 1.520 105 107 105 98 89 >1.00 E4 >1.00 E4 >1.00 E4
RPMI-8226 0.795 2.712 2.696 2.643 2.631 2.033 1.772 99 96 96 65 51 >1.00 E4 >1.00 E4 >1.00 E4
SR 0.240 1.406 1.428 1.455 1.447 0.743 0.547 102 104 104 43 26 7.70 E6 >1.00 E4 >1.00 E4
Non-Small Cell Lung Cancer
A549/ATCC 0.253 1.319 1.262 1.286 1.293 0.664 0.699 95 97 98 39 42 6.39 E6 >1.00 E4 >1.00 E4
EKVX 0.720 1.673 1.653 1.674 1.611 1.288 1.158 98 100 94 60 46 5.05 E5 >1.00 E4 >1.00 E4
HOP-62 0.421 1.062 1.027 1.005 1.004 0.703 0.226 94 91 91 44 46 7.44 E6 3.06 E5 >1.00 E4
HOP-92 1.396 2.139 1.989 1.969 1.916 1.721 1.468 80 77 70 44 10 5.77 E6 >1.00 E4 >1.00 E4
NCI-H226 0.630 1.349 1.341 1.347 1.353 0.743 0.397 99 100 101 16 37 3.94 E6 1.98 E5 >1.00 E4
NCI-H23 0.514 1.382 1.406 1.388 1.432 0.909 0.444 103 101 106 45 14 8.40 E6 5.88 E5 >1.00 E4
NCI-H322M 0.715 1.092 1.171 1.117 1.152 0.807 0.725 121 106 116 24 3 5.23 E6 >1.00 E4 >1.00 E4
NCI-H460 0.154 1.363 1.434 1.455 1.455 0.141 0.148 106 108 108 9 4 3.13 E6 8.41 E6 >1.00 E4
NCI-H522 0.607 1.456 1.487 1.552 1.545 0.449 0.447 104 111 110 26 21 2.77 E6 6.45 E6 >1.00 E4
Colon cancer
COLO 205 0.266 1.128 1.184 1.205 1.201 1.116 1.068 107 109 109 99 93 >1.00 E4 >1.00 E4 >1.00 E4
HCC-2998 0.474 1.476 1.465 1.511 1.541 1.095 1.027 99 103 106 62 55 >1.00 E4 >1.00 E4 >1.00 E4
HCT-116 0.171 1.540 1.590 1.536 1.486 0.230 0.130 104 100 96 4 24 3.18 E6 1.42 E5 >1.00 E4
HCT-15 0.193 1.375 1.367 1.331 1.311 1.073 0.924 99 96 95 74 62 >1.00 E4 >1.00 E4 >1.00 E4
HT-29 0.155 0.883 0.941 0.960 0.995 0.783 0.729 108 111 115 86 79 >1.00 E4 >1.00 E4 >1.00 E4
KM 12 0.415 1.793 1.855 1.848 1.826 1.480 1.333 104 104 102 77 67 >1.00 E4 >1.00 E4 >1.00 E4
SW-620 0.124 0.842 0.854 0.886 0.871 0.629 0.455 102 106 104 70 46 6.90 E5 >1.00 E4 >1.00 E4
CNS cancer
SF-268 0.346 1.231 1.271 1.264 1.230 0.395 0.360 104 104 100 6 9 3.38 E6 >1.00 E4 >1.00 E4
SF-295 0.701 1.779 1.730 1.697 1.717 1.242 0.895 95 92 94 50 18 1.01 E5 >1.00 E4 >1.00 E4
SF-539 0.492 1.757 1.742 1.711 1.690 0.707 0.269 99 96 95 17 45 3.76 E6 1.87 E5 >1.00 E4
SNB-19 0.417 1.200 1.200 1.226 1.256 0.666 0.334 100 103 107 32 20 5.73 E6 4.12 E5 >1.00 E4
SNB-75 0.662 1.136 1.049 1.108 1.108 0.574 0.172 82 94 94 13 74 2.57 E6 7.51 E6 4.02 E5
U251 0.279 1.391 1.388 1.364 1.378 0.531 0.240 100 98 99 23 14 4.37 E6 4.12 E5 >1.00 E4
Melanoma
LOX IMVI 0.141 0.945 0.912 0.939 0.838 0.582 0.429 96 99 87 55 36 1.78 E5 >1.00 E4 >1.00 E4
M14 0.284 1.199 1.199 1.164 1.236 1.291 0.865 100 96 104 110 63 >1.00 E4 >1.00 E4 >1.00 E4
MDA-MB-435 0.340 1.243 1.221 1.237 1.257 0.981 0.971 98 99 101 71 70 >1.00 E4 >1.00 E4 >1.00 E4
SK-MEL-2 0.821 2.277 2.389 2.405 2.415 1.322 0.849 108 109 110 34 9 6.20 E6 >1.00 E4 >1.00 E4
SK-MEL-28 0.485 1.120 1.157 1.144 1.216 1.034 0.797 106 104 115 86 49 9.47 E5 >1.00 E4 >1.00 E4
SK-MEL-5 0.316 1.746 1.763 1.736 1.689 1.062 0.749 101 99 96 52 30 1.25 E5 >1.00 E4 >1.00 E4
UACC-257 0.466 1.075 1.065 1.047 1.051 0.876 0.800 98 95 96 67 55 >1.00 E4 >1.00 E4 >1.00 E4
UACC-62 0.598 1.775 1.770 1.823 1.807 1.076 0.152 100 104 103 41 75 7.05 E6 2.25 E5 6.12 E5
Ovarian cancer
IGROV1 0.499 1.085 1.175 1.184 1.203 0.532 0.377 115 117 120 6 24 4.10 E6 1.54 E5 >1.00 E4
OVCAR3 0.282 0.859 0.917 0.918 0.907 0.212 0.077 110 110 108 25 73 2.74 E6 6.51 E6 3.36 E5
OVCAR4 0.468 0.864 0.875 0.901 0.908 0.370 0.345 103 109 111 21 26 2.90 E6 6.93 E6 >1.00 E4
OVCAR5 0.433 1.386 1.343 1.318 1.334 1.142 0.932 95 93 95 74 52 >1.00 E4 >1.00 E4 >1.00 E4
OVCAR8 0.253 1.037 1.078 1.054 1.007 0.337 0.267 105 102 96 11 2 3.47 E6 >1.00 E4 >1.00 E4
NCI-RES 0.442 1.482 1.559 1.533 1.496 0.636 0.518 107 105 101 19 7 4.18 E6 >1.00 E4 >1.00 E4
SK-OV-3 0.579 1.289 1.307 1.289 1.313 0.886 0.412 103 100 103 43 29 7.70 E6 3.97 E5 >1.00 E4
Renal cancer
786-0 0.582 1.943 1.856 1.893 1.781 0.955 0.518 94 96 88 27 11 4.25 E6 5.15 E5 >1.00 E4
A498 0.798 1.312 1.305 1.340 1.315 1.035 0.758 98 105 100 46 5 8.47 E6 7.98 E5 >1.00 E4
ACHN 0.213 1.255 1.303 1.297 1.235 0.626 0.401 105 104 98 40 18 6.63 E6 >1.00 E4 >1.00 E4
CAKI-1 0.570 1.525 1.565 1.510 1.367 1.057 1.184 104 98 83 51 64 >1.00 E4 >1.00 E4 >1.00 E4
RXF-393 0.464 1.040 1.037 1.072 1.032 0.844 0.413 99 106 99 66 11 1.61 E5 7.20 E5 >1.00 E4
SN12C 0.431 1.502 1.562 1.588 1.540 1.009 0.686 106 108 104 54 24 1.35 E5 >1.00 E4 >1.00 E4
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Table 1 (continued)
NSC: D-753447/1 Experiment ID: 1009 NS13 Units: Molar
COMI: SIH6 (96135) Strain reagent: SRB Dual Pass SSPL: 0XXS
Parent cell line Time Mean optical densities Percent growth GI50 TGI LC50
Zero Control 8.0 7.0 6.0 5.0 4.0 8.0 7.0 6.0 5.0 4.0
TK-10 0.544 1.369 1.391 1.398 1.447 0.979 0.490 103 104 109 53 10 1.11 E5 6.92 E5 >1.00 E4
UO-31 0.679 1.233 1.184 1.164 1.200 0.792 0.669 91 87 94 20 2 3.95 E6 8.50 E5 >1.00 E4
Prostate cancer
PC-3 0.413 1.309 1.284 1.300 1.265 0.619 0.534 97 99 95 23 14 4.22 E6 >1.00 E4 >1.00 E4
DU-145 0.298 1.204 1.243 1.214 1.194 0.765 0.566 104 101 99 51 30 1.17 E5 >1.00 E4 >1.00 E4
Breast cancer
MCF7 0.288 1.086 1.176 1.076 1.106 0.607 0.417 111 99 102 40 16 >1.00 E4 >1.00 E4 >1.00 E4
MDA-MB-231 0.503 1.182 1.203 1.195 1.207 0.925 0.684 103 102 104 62 27 >1.00 E4 >1.00 E4 >1.00 E4
HS-578T 0.636 1.257 1.272 1.291 1.271 0.956 0.733 102 105 102 51 16 >1.00 E4 >1.00 E4 >1.00 E4
BT-549 0.866 1.733 1.743 1.689 1.729 0.994 0.555 101 95 100 15 36 >1.00 E4 >1.00 E4 >1.00 E4
T-47D 0.575 1.094 .055 1.088 1.071 0.647 0.610 93 99 96 14 7 >1.00 E4 >1.00 E4 >1.00 E4
MDA-MB-468 0.462 1.057 1.036 1.097 1.069 0.896 0.720 96 105 102 73 43 >1.00 E4 >1.00 E4 >1.00 E4
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5.08), and NCI-H522 (GI50 value 5.56 &and TGI value
5.19), Colon HCT-116 cancer cell lines (GI50 value of
5.50 and TGI value 4.85), CNS cancer cell lines; SNB-19
(GI50 value 5.24 and TGI value 4.39), SF-539 (GI50 value
5.43 and TGI value 4.73), and U251 (GI50 value 5.36
and TGI value 4.38), Melanoma UACC-62 cancer cell line
(GI50 value 5.15 and TGI value 4.65), Ovarian cancer cell
lines; IGROV1 (GI50 value 5.31 and TGI value 4.81), OV-
CAR 3 (GI50 value 5.56 and TGI value 5.19), and SK-OV-
3 (GI50 value 5.11 and TGI value 4.40), Renal cancer cell
lines; 786-0 (GI50 value 5.37 and TGI value 4.29), A498
(GI50 value 5.07 and TGI value 4.10), RXF-393 (GI50 va-
lue 4.79 and TGI value 4.14), TK-10 (GI50 value 4.96
and TGI value 4.16), and UO-31 (GI50 value 5.40 and
TGI value 4.07), Breast BT-549 cancer cell line with GI50 va-
lue of 5.42 and TGI value of 4.71. It was also found to be
active at median lethal concentration against CNS SNB-75
(LC50 value 4.40), Melanoma UACC-62 (LC50 value
4.21), and Ovarian OVCAR 3 cancer cell line (LC50 value
4.47) at 5-log dose range as shown in Tables 1 and 2. The
highest activity of this compound might be because of its struc-
tural resemblance with lapatinib since it contain 4-chloro ben-
zylideneamine group at C-3 position of quinazoline which
suppose to block the hydrophobic pocket of tyrosine kinase
(Fig. 3).
5. Conclusion
A novel 3-(substituted benzylideneamino)-7-chloro-2-phenyl
quinazoline-4(3H)-one (7–27) has been synthesized. We chan-
ged the methodology for the synthesis of 3-amino 7-chloro-2-
phenyl quinazolin-4(3H)-one 6 to fusion reaction at 250 C, in-
stead of using solvent, to avoid the problem of ring opening,
which is commonly observed while synthesizing quinazolines
from benzoxazinone. Fusion is more convenient and time sav-
ing method since it takes only 0.5 h, where conventional takes
3.0 h for the reaction. By using this new methodology the prep-
aration of 3-amino 7-chloro-2-phenyl quinazolin-4(3H)-one 6
is simple, time-saving and eco-friendly process without solventand also avoid the problem of ring opening. NCI selected, 7-
chloro-3-{[(4-chlorophenyl) methylidene] amino}-2-phenylqui-
nazolin-4(3H)-one 12, with GI50 value of 5.59 M, TGI value
of 5.12 M, and LC50 value of 4.40 M showed remarkable
activity against CNS SNB-75 cancer cell line. Rational ap-
proach and QSAR techniques enabled the understanding of
the pharmacophoric requirement for quinazoline derivatives.
The overall outcome of this model revealed that: (i) the quinaz-
oline ring is satisfactory backbone for antitumor activity, (ii)
the presence of hydrophobic group at 3 position of quinazoline
enhances the activity. These preliminary encouraging results of
biological screening of the tested compounds could offer an
excellent framework in this ﬁeld that may lead to discovery
of potent antitumor agent.
6. Experimental
All chemicals and solvents were supplied by Merck, S.D. Fine
Chemical Limited, Mumbai. All the solvents were distilled and
dried before use. The reactions were monitored with the help
of thin-layer chromatography using pre-coated aluminum
sheets with GF254 silica gel, 0.2 mm layer thickness (E. Merck).
Melting points of the synthesized compounds were recorded
on the Veego (VMP-MP) melting point apparatus. IR spec-
trum was acquired on a Shimadzu Infra Red Spectrometer,
(model FTIR-8400S). Both 1H NMR (DMSO) spectra of the
synthesized compounds were performed with Bruker Avance-
II 400 NMR Spectrometer operating at 400 MHz in SAIF,
Punjab University (Chandigarh). Chemical shifts were mea-
sured relative to internal standard TMS (d: 0). 13C NMR spec-
tra were recorded at 67.8 MHz on the same instrument with
internal TMS (d: 0, DMSO). Chemical shifts are reported in
d scale (ppm). Elemental analyses were performed at the
Microanalytical Laboratory of the SAIF, Punjab University.
6.1. Synthesis of 7-chloro 2-phenyl-benzo[d] [1,3] oxazine-4-
one (3)
4-Chloro 2-amino benzoic acid 1 (0.1 mole) was dissolved in
minimum volume of dry pyridine (30 ml) by shaking. To this
Table 2 National Cancer Institute developmental therapeu-
tics program in-vitro mean testing results of compound 12.
NSC: D-753447/1 Experiment ID: 1009 NS13 Units: Molar
COMI: SIH6 (96135) Strain reagent: SRB Dual Pass SSPL: 0XXS
Cell Lines log10 GI50 log10 TGI log10 LC50
Leukemia
CCRFCEM >4.00 >4.00 >4.00
MOLT-4 >4.00 >4.00 >4.00
RPMI-8226 >4.00 >4.00 >4.00
SR 5.11 >4.00 >4.00
Non-Small Cell Lung Cancer
A549/ATCC 5.19 >4.00 >4.00
EKVX 4.30 >4.00 >4.00
HOP-62 5.13 4.51 >4.00
HOP-92 5.24 >4.00 >4.00
NCI-H226 5.40 4.70 >4.00
NCI-H23 5.08 4.23 >4.00
NCI-H322M 5.28 >4.00 >4.00
NCI-H460 5.51 5.08 >4.00
NCI-H522 5.56 5.19 >4.00
Colon cancer
COLO 205 >4.00 >4.00 >4.00
HCC-2998 >4.00 >4.00 >4.00
HCT-116 5.50 4.85 >4.00
HCT-15 >4.00 >4.00 >4.00
HT-29 >4.00 >4.00 >4.00
KM 12 >4.00 >4.00 >4.00
SW-620 4.16 >4.00 >4.00
CNS cancer
SF-268 5.47 >4.00 >4.00
SF-295 4.99 >4.00 >4.00
SF-539 5.43 4.73 >4.00
SNB-19 5.24 4.39 >4.00
SNB-75 5.59 5.12 4.40
U251 5.36 4.38 >4.00
Melanoma
LOXIMVI 4.75 >4.00 >4.00
M14 >4.00 >4.00 >4.00
MDA-MB-435 >4.00 >4.00 >4.00
SK-MEL-2 5.21 >4.00 >4.00
SK-MEL-28 4.02 >4.00 >4.00
SK-MEL-5 4.90 >4.00 >4.00
UACC-257 >4.00 >4.00 >4.00
UACC-62 5.15 4.65 4.21
Ovarian cancer
IGROV1 5.31 4.81 >4.00
OVCAR3 5.56 5.19 4.47
OVCAR4 5.54 >4.00 >4.00
OVCAR5 >4.00 >4.00 >4.00
OVCAR8 5.46 >4.00 >4.00
NCI-RES 5.38 >4.00 >4.00
SK-OV-3 5.11 4.40 >4.00
Renal cancer
786-0 5.37 4.29 >4.00
A498 5.07 4.10 >4.00
ACHN 5.18 >4.00 >4.00
CAKI-1 >4.00 >4.00 >4.00
RXF-393 4.79 4.14 >4.00
SN12C 4.87 >4.00 >4.00
TK-10 4.96 4.16 >4.00
UO-31 5.40 4.07 >4.00
Table 2 (continued)
NSC: D-753447/1 Experiment ID: 1009 NS13 Units: Molar
COMI: SIH6 (96135) Strain reagent: SRB Dual Pass SSPL: 0XXS
Cell Lines log10 GI50 log10 TGI log10 LC50
Prostate cancer
PC-3 5.37 >4.00 >4.00
DU-145 4.93 >4.00 >4.00
Breast cancer
MCF7 5.16 >4.00 >4.00
MDA-MB-231 4.66 >4.00 >4.00
HS-578T 4.96 >4.00 >4.00
BT-549 5.42 4.71 >4.00
T-47D 5.44 >4.00 >4.00
MDA-MB-468 4.23 >4.00 >4.00
44 M.N. Noolvi, H.M. Patelsolution benzoyl chloride 2 (0.2 mole) taken in dry pyridine
(30 ml), was added slowly with constant stirring. When the
addition was completed (the operation of addition required
half an hour), the resultant solution was subjected to vigorous
stirring for one hour mechanically subsequently, it was left as
such for one hour at room temperature and treated with a
solution of sodium bicarbonate (10%). Addition of sodium
bicarbonate solution was continued till the effervescence due
to the evolution of carbon-dioxide ceased. The separated solid
was allowed to settle down and ﬁltered off. It was washed with
cold water repeatedly till there was no smell of pyridine and
unreacted benzoyl chloride. The crude benzo-oxazine was
dried in vacuum overnight and recrystallization from diluted
ethanol afforded analytically pure sample of 2-phenyl-benzo[d]
[1,3] oxazin-4-one 3 as white crystalline mass. Yield 82%; mp
195–198 C. IR (KBr, mmax, cm1): 3062 (C–H), 1745 (C‚O),
1510 (C‚N), 1480 (C‚C), 1364 (C–N), 771 (C–Cl). 1H NMR
(DMSO-d6) d ppm: 7.60–8.21 (m, 8H, Ar-H).
13C NMR
(DMSO-d6) d ppm: 164.2, 158.4, 156.2, 140.4, 136.2, 134.6,
130.8, 128.6, 128.4, 126.6, 124.4, 114.4. Anal. Calcd for
C14H8ClNO2: C, 65.26; H, 3.13; N, 5.44. Found: C, 65.42;
H, 3.04; N, 5.65%.
6.2. Synthesis of isomers of N-(5-chloro-2-(hydrazine carbonyl)
phenyl) benzamide (4) and 3-amino 7-chloro-2-phenyl
quinazolin-4(3H)-one (5)
A mixture of 7-chloro 2-phenyl-benzo[d] [1,3] oxazine-4-one 3
(0.01 mol) and hydrazine hydrate (0.01 mol) in dry pyridine
(50 ml) was heated under reﬂux for 3 h. Subsequently, mixture
was poured into water (containing few drops of HCl) solid
thus separated was ﬁltered, washed repeatedly with water. It
was dried and crystallized from ethanol. Isomers were sepa-
rated by column chromatography using benzene: acetone in
7:3 ratio.
6.2.1. N-(5-Chloro-2-(hydrazine carbonyl) phenyl) benzamide
(4)
This compound was prepared, puriﬁed, and separated as per
the above mentioned procedure: yield 35%; mp 215–217 C.
IR (KBr, mmax, cm
1): 3212 (s), 1560 (b) (NH), 3057 (C–H),
1665 (C‚O), 1484 (C‚C), 748 (C–Cl). 1H NMR (DMSO-
d6) d ppm: 6.21 (s, 2H, NH2), 7.14–8.60 (m, 8H, Ar-H),
Synthesis, method optimization, anticancer activity of 2,3,7-trisubstituted quinazoline derivatives 4510.19 (s, 1H, –NHCO–), 9.12 (s, 1H, –CONH–). 13C NMR
(DMSO-d6) d ppm: 168.6, 168.2, 145.6, 142.7, 136.6, 132.1,
130.3, 128.8, 126.8, 122.4, 120.5, 118.4. Anal. Calcd for
C14H12ClN3O2: C, 58.04; H, 4.17; N, 14.50. Found: C, 58.18;
H, 4.42; N, 14.81%.
6.2.2. 3-Amino 7-chloro-2-phenyl quinazolin-4(3H)-one (5)
This compound was prepared, puriﬁed and separated as per
the above mentioned procedure: yield 41%; mp 206–209 C.
IR (KBr, mmax, cm
1): 3270 (s), 1582 (b) (NH2), 3078 (CH),
1666 (C‚O), 1564 (C‚N), 1491 (C‚C), 1371 (C–N), 762
(C–Cl). 1H NMR (DMSO-d6) d ppm: 5.25 (s, 2H, NH2),
7.14–8.18 (m, 8H, Ar-H). 13C NMR (DMSO-d6) d ppm:
164.8, 158.4, 154.6, 138.6, 132.6, 132.6, 130.8, 130.6, 128.6,
127.6, 120.8. Anal. Calcd for C14H10ClN3O: C, 61.89; H,
3.71; N, 15.47. Found: C, 61.66; H, 3.78; N, 15.68%.
6.2.3. Optimized method for the synthesis of 3-amino 7-chloro-2-
phenyl quinazolin-4(3H)-one (6)
A mixture of 7-chloro 2-phenyl-benzo[d] [1,3] oxazine-4-one 3
and hydrazine hydrate was fused together at 250 C in an oil
bath for 0.5 h. The mixture was cooled and methanol was
added to the mixture. The separated solid was collected by ﬁl-
tration, washed with methanol, dried, and crystallized from
ethanol. Yield 68%; mp 206–209 C. IR (KBr, mmax, cm1):
3270 (s), 1582 (b) (NH2), 3078 (CH), 1666 (C‚O), 1564
(C‚N), 1491 (C‚C), 1371 (C–N), 762 (C–Cl). 1H NMR
(DMSO-d6) d ppm: 5.25 (s, 2H, NH2), 7.14–8.18 (m, 8H,
Ar-H). 13C NMR (DMSO-d6) d ppm: 164.8, 158.4, 154.6,
138.6, 132.6, 132.6, 130.8, 130.6, 128.6, 127.6, 120.8. Anal.
Calcd for C14H10ClN3O: C, 61.89; H, 3.71; N, 15.47. Found:
C, 61.46; H, 3.85; N, 15.66%.
6.3. General procedure for the synthesis of 3-(substituted
benzylideneamino)-7-chloro-2-phenyl quinazoline-4(3H)-one
(7–27)
A mixture of 3-amino-7-chloro-2-phenyl-3H-quinazoline-4-
one 6 and different aldehydes in equimolar quantities in glacial
acetic acid was heated under reﬂux for six hours. The solution
was cooled and poured carefully into crushed ice. A solid sep-
arated out which was allowed to settle down. It was ﬁltered off,
washed successively with water and dried. The solid thus ob-
tained was on recrystallization from diluted ethanol afforded
white crystalline solid mass.
6.3.1. 3-(Anthracene-9-yl methyleneamino)-7-chloro-2-phenyl
quinazoline-4(3H)-one (7)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 62%; mp 288–291 C. IR (KBr,
mmax, cm
1): 3052 (CH), 1650 (C‚O), 1545 (C‚N), 1495
(C‚C), 1384 (C–N), 752 (C–Cl). 1H NMR (DMSO-d6) d
ppm: 6.54–8.28 (m, 17H, Ar-H), 8.77 (s, 1H, N‚CH). 13C
NMR (DMSO-d6) d ppm: 170.5, 168.7, 156.6, 154.5, 146.8,
140.8, 132.8, 131.2, 131.1, 129.9, 129.8, 129.2, 129.0, 125.6,
124.6, 123.8, 122.2, 118.0. Anal. Calcd for C29H18ClN3O: C,
75.73; H, 3.94; N, 9.14. Found: C, 75.64; H, 3.64; N, 9.06%.
6.3.2. 3-(Benzylideneamino)-7-chloro-2-phenyl quinazoline-
4(3H)-one (8)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 68%; mp 234–236 C. IR (KBr,mmax, cm
1): 3089 (CH), 1654 (C‚O), 1552 (C‚N), 1488
(C‚C), 1386 (C–N), 724 (C–Cl). 1H NMR (DMSO-d6) d
ppm: 7.41–8.28 (m, 13H, Ar-H), 9.29 (s, 1H, N‚CH).
13CNMR (DMSO-d6) d ppm: 170.7, 168.6, 160.4, 156.4,
154.2, 140.4, 135.7, 132.0, 131.2, 131.1, 130.6, 129.8, 129.2,
125.6, 122.6, 118.0. Anal. Calcd for C21H14ClN3O: C, 70.10;
H, 3.92; N, 11.68. Found: C, 70.24; H, 3.68; N, 11.51%.
6.3.3. 3-(3-Bromo benzylideneamino)-7-chloro-2-phenyl
quinazoline-4(3H)-one (9)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 71%; mp 248–251 C. IR (KBr,
mmax, cm
1): 3065 (CH), 1634 (C‚O), 1556 (C‚N), 1494
(C‚C), 1389 (C–N), 735 (C–Cl), 685 (C–Br). 1H NMR
(DMSO-d6) d ppm: 7.05–8.36 (m, 12H, Ar-H), 8.98 (s, 1H,
N‚CH). 13C NMR (DMSO-d6) d ppm: 170.7, 168.6, 156.2,
154.6, 152.5, 140.2, 136.9, 134.9, 132.7, 131.2, 131.1, 130.2,
129.8, 129.2, 125.1, 123.7, 122.4, 118.0. Anal. Calcd for
C21H13BrClN3O: C, 57.49; H, 2.99; N, 9.58. Found: C,
57.36; H, 2.91; N, 9.45%.
6.3.4. 3-(4-Cyano benzylideneamino)-7-chloro-2-phenyl
quinazoline-4(3H)-one (10)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 82%; mp 222–225 C. IR (KBr,
mmax, cm
1): 3071 (CH), 2245 (cyano), 1645 (C‚O), 1534
(C‚N), 1488 (C‚C), 1392 (C–N), 765 (C–Cl). 1H NMR
(DMSO-d6) d ppm: 7.41–8.28 (m, 12H, Ar-H), 9.29 (s, 1H,
N‚CH). 13C NMR (DMSO-d6) d ppm: 170.7, 168.3, 160.8,
156.4, 154.5, 141.2, 140.2, 135.3, 131.2, 131.1, 129.8, 125.4,
126.3, 122.6, 118.0, 116.6, 114.6. Anal. Calcd for
C22H13ClN4O: C, 68.67; H, 3.41; N, 14.56. Found: C, 68.75;
H, 3.24; N, 14.39%.
6.3.5. 3-(2-Chloro benzylideneamino)-7-chloro-2-phenyl
quinazoline-4(3H)-one (11)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 83%; mp 211–214 C. IR (KBr,
mmax, cm
1): 3058 (CH), 1647 (C‚O), 1536 (C‚N), 1490
(C‚C), 1421 (C–N), 756 (C–Cl). 1H NMR (DMSO-d6) d
ppm: 7.12–8.28 (m, 12H, Ar-H), 9.12 (s, 1H, N‚CH). 13C
NMR (DMSO-d6) d ppm: 170.8, 168.4, 156.3, 154.2, 146.6,
140.1, 136.7, 135.9, 132.4, 131.1, 129.8, 129.2, 125.4, 125.2,
126.9, 122.4, 118.0. Anal. Calcd for C21H13Cl2N3O: C, 63.98;
H, 3.32; N, 10.66. Found: C, 63.88; H, 3.27; N, 10.63%.
6.3.6. 3-(4-Chloro benzylideneamino)-7-chloro-2-phenyl
quinazoline-4(3H)-one (12)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 63%; mp 228–230 C. IR (KBr,
mmax, cm
1): 3052 (CH), 1657 (C‚O), 1530 (C‚N), 1495
(C‚C), 1412 (C–N), 725 (C–Cl). 1H NMR (DMSO-d6) d
ppm: 7.34–8.61 (m, 12H, Ar-H), 9.23 (s, 1H, N‚CH). 13C
NMR (DMSO-d6) d ppm: 170.6, 168.3, 160.4, 156.7, 154.5,
140.1, 136.6, 132.8, 131.6, 131.2, 131.1, 129.9, 129.8, 129.2,
125.4, 122.4, 118.0. Anal. Calcd for: C21H13Cl2N3O C, 63.98;
H, 3.32; N, 10.66. Found: C, 63.82; H, 3.36; N, 10.58%.
6.3.7. 3-(4-Dimethylamino benzylideneamino)-7-chloro-2-
phenyl quinazoline-4(3H)-one (13)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 52%; mp 218–220 C. IR (KBr,
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1): 3059 (CH), 1659 (C‚O), 1538 (C‚N), 1478
(C‚C), 1423 (C–N), 734 (C–Cl). 1H NMR (DMSO-d6) d
ppm: 2.48 (s, 6H, CH3), 7.39–8.39 (m, 12H, Ar-H), 9.34 (s,
1H, N‚CH). 13C NMR (DMSO-d6) d ppm: 170.8, 168.3,
160.8, 156.6, 156.1, 154.2, 140.1, 131.2, 131.1, 129.8, 129.3,
129.2, 125.4, 123.6, 122.4, 118.0, 114.8, 41.6. Anal. Calcd for
C23H19ClN4O: C, 68.57; H, 4.75; N, 13.91. Found: C, 68.52;
H, 4.78; N, 13.63%.6.3.8. 3-(3-Methoxy 4-hydroxy benzylideneamino)-7-chloro-2-
phenyl quinazoline-4(3H)-one (14)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 78%; mp 260–263 C. IR (KBr,
mmax, cm
1): 3410 (OH), 3058 (CH), 1678 (C‚O), 1562
(C‚N), 1485 (C‚C), 1435 (C–N), 710 (C–Cl). 1H NMR
(DMSO-d6) d ppm: 3.94 (s, 3H, OCH3), 7.51–8.34 (m, 11H,
Ar-H), 8.90 (s, 1H, N‚CH), 10.12 (s, 1H, OH). 13C NMR
(DMSO-d6) d ppm: 170.8, 168.7, 156.2, 154.5, 153.8, 152.4,
150.1, 140.8, 131.9, 131.2, 131.1, 129.8, 129.2, 125.4, 122.8,
122.3, 118.0, 116.6, 114.6. Anal. Calcd for C22H16ClN3O3:
C, 65.11; H, 3.97; N, 10.35. Found: C, 65.18; H, 3.63; N,
10.21%.
6.3.9. 3-(4-Methoxy benzylideneamino)-7-chloro-2-phenyl
quinazoline-4(3H)-one (15)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 62%; mp 251–254 C. IR (KBr,
mmax, cm
1): 3055 (CH), 1664 (C‚O), 1540 (C‚N), 1489
(C‚C), 1414 (C–N), 714 (C–Cl). 1H NMR (DMSO-d6) d
ppm: 3.96 (s, 3H, OCH3), 7.10–8.26 (m, 12H, Ar-H), 9.11 (s,
1H, N‚CH). 13C NMR (DMSO-d6) d ppm: 170.4, 168.2,
164.1, 160.4, 156.2, 154.5, 140.8, 131.2, 131.1, 129.8, 129.2,
125.4, 126.0, 122.4, 118.0, 116.4, 54.4. Anal. Calcd for
C22H16ClN3O2: C, 67.78; H, 4.14; N, 10.78. Found: C, 67.81;
H, 4.05; N, 10.67%.6.3.10. 3-(2-Hydroxy benzylideneamino)-7-chloro-2-phenyl
quinazoline-4(3H)-one (16)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 69%; mp 210–213 C. IR (KBr,
mmax, cm
1): 3390 (OH), 3088 (CH), 1656 (C‚O), 1648
(C‚C), 1510 (C‚N), 1498 (C‚C), 1445 (C–N), 724 (C–Cl).
1H NMR (DMSO-d6) d ppm: 7.56–8.30 (m, 12H, Ar-H),
9.10 (s, 1H, N‚CH), 11.99 (s, 1H, OH). 13C NMR (DMSO-
d6) d ppm: 170.4, 168.3, 160.6, 156.1, 154.2, 146.1, 140.4,
134.4, 131.2, 131.1, 129.8, 129.2, 125.5, 125.4, 122.2, 121.1,
118.0, 114.4, 112.4. Anal. Calcd for C21H14ClN3O2: C, 67.12;
H, 3.75; N, 11.18. Found: C, 67.32; H, 3.72; N, 11.05%.6.3.11. 3-(4-Hydroxy benzylideneamino)-7-chloro-2-phenyl
quinazoline-4(3H)-one (17)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 72%; mp 244–247 C. IR (KBr,
mmax, cm
1): 3418 (OH), 3079 (CH), 1644 (C‚O), 1524
(C‚N), 1478 (C‚C), 1405 (C–N), 768 (C–Cl) cm1. 1H
NMR (DMSO-d6) d ppm: 7.16–8.70 (m, 12H, Ar-H), 9.16 (s,
1H, N‚CH), 11.99 (s, 1H, OH). 13C NMR (DMSO-d6) d
ppm: 170.4, 168.6, 164.8, 160.3, 156.6, 154.2, 140.1, 131.6,
131.2, 131.1, 129.8, 129.2, 125.4, 126.5, 122.4, 118.0, 114.2.
Anal. Calcd for C21H14ClN3O2: C, 67.12; H, 3.75; N, 11.18.
Found: C, 67.04; H, 3.67; N, 11.26%.6.3.12. 3-(2,5-Dimethoxy benzylideneamino)-7-chloro-2-phenyl
quinazoline-4(3H)-one (18)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 78%; mp 251–254 C. IR (KBr,
mmax, cm
1): 3071 (CH), 1646 (C‚O), 1522 (C‚N), 1491
(C‚C), 1428 (C-N), 745 (C–Cl). 1H NMR (DMSO-d6) d
ppm: 3.96 (s, 6H, OCH3), 7.10–8.64 (m, 11H, Ar-H), 8.88 (s,
1H, N‚CH). 13C NMR (DMSO-d6) d ppm: 170.4, 168.3,
156.6, 156.1, 154.4, 150.9, 146.2, 140.2, 131.2, 131.1, 129.8,
129.2, 125.4, 122.6, 118.0, 116.9, 116.6, 114.6, 112.4, 54.2.
Anal. Calcd for C23H18ClN3O3: C, 65.79; H, 4.32; N, 10.01.
Found: C, 65.98; H, 4.21; N, 10.14%.
6.3.13. 3-(4-Methyl benzylideneamino)-7-chloro-2-phenyl
quinazoline-4(3H)-one (19)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 62%; mp 223–226 C. IR (KBr,
mmax, cm
1): 3078 (CH), 1662 (C‚O), 1512 (C‚N), 1498
(C‚C), 1434 (C–N), 724 (C–Cl). 1H NMR (DMSO-d6) d
ppm: 2.48 (s, 3H, CH3), 7.12–8.87 (m, 12H, Ar-H), 8.90 (s,
1H, N‚CH). 13C NMR (DMSO-d6) d ppm: 170.8, 168.3,
160.2, 156.4, 154.2, 142.7, 140.2, 131.7, 131.2, 131.1, 130.5,
129.8, 129.2, 125.4, 126.1, 122.4, 118.0, 22.4. Anal. Calcd for
C22H16ClN3O: C, 70.68; H, 4.31; N, 11.24. Found: C, 70.66;
H, 4.12; N, 11.65%.
6.3.14. 3-(3-Nitro benzylideneamino)-7-chloro-2-phenyl
quinazoline-4(3H)-one (20)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 70%; mp 246–250 C. IR (KBr,
mmax, cm
1): 3076 (CH), 1648 (C‚O), 1518 (C‚N), 1545,
1354 (NO2), 1496 (C‚C), 1421 (C–N), 752 (C–Cl). 1H
NMR (DMSO-d6) d ppm: 7.18–8.33 (m, 12H, Ar-H), 9.28 (s,
1H, N‚CH). 13C NMR (DMSO-d6) d ppm: 170.1, 169.2,
168.3, 156.4, 154.2, 150.4, 140.2, 136.8, 132.4, 131.2, 131.1,
130.2, 129.8, 129.2, 125.4, 123.6, 122.1, 118.0. Anal. Calcd
for C21H13ClN4O3: C, 62.31; H, 3.24; N, 13.84. Found: C,
62.16; H,3.32; N, 13.63%.
6.3.15. 3-(4-Nitro benzylideneamino)-7-chloro-2-phenyl
quinazoline-4(3H)-one (21)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 71%; mp 232–234 C. IR (KBr,
mmax, cm
1): 3072 (CH), 1676 (C‚O), 1528 (C‚N), 1554,
1348 (NO2), 1486 (C‚C), 1428 (C–N), 760 (C–Cl).
1H
NMR (DMSO-d6) d ppm: 7.65–8.53 (m, 12H, Ar-H), 9.45 (s,
1H, N‚CH). 13C NMR (DMSO-d6) d ppm: 170.8, 169.4,
168.3, 160.2, 156.4, 154.1, 144.7, 140.2, 131.2, 130.1, 129.8,
129.2, 125.7, 125.4, 122.6, 121.1, 118.0. Anal. Calcd for
C21H13ClN4O3: C, 62.31; H, 3.24; N, 13.84. Found: C, 62.29;
H, 3.21; N, 13.88%.
6.3.16. 3-(2-Nitro benzylideneamino)-7-chloro-2-phenyl
quinazoline-4(3H)-one (22)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 62%; mp 262–265 C. IR (KBr,
mmax, cm
1): 3064 (CH), 1676 (C‚O), 1510 (C‚N), 1561,
1352 (NO2), 1484 (C‚C), 1436 (C–N), 736 (C–Cl). 1H
NMR (DMSO-d6) d ppm: 7.65–8.43 (m, 12H, Ar-H), 9.12 (s,
1H, N‚CH). 13C NMR (DMSO-d6) d ppm: 170.3, 168.8,
168.4, 156.3, 154.1, 146.1, 140.8, 136.8, 132.8, 130.2, 130.2,
130.1, 130, 129.8, 129.2, 125.4, 124.6, 122.6, 121.1, 118.0. Anal.
Synthesis, method optimization, anticancer activity of 2,3,7-trisubstituted quinazoline derivatives 47Calcd for C21H13ClN4O3: C, 62.31; H, 3.24; N, 13.84. Found:
C, 62.38; H, 3.16; N, 13.98%.
6.3.17. 3-(4-Bromo benzylideneamino)-7-chloro-2-phenyl
quinazoline-4(3H)-one (23)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 68%; mp 268–270 C. IR (KBr,
mmax, cm
1): 3068 (CH), 1656 (C‚O), 1538 (C‚N), 1486
(C‚C), 1398 (C–N), 764 (C–Cl), 671 (C–Br). 1H NMR
(DMSO-d6) d ppm: 7.16–8.54 (m, 12H, Ar-H), 9.35 (s, 1H,
N‚CH). 13C NMR (DMSO-d6) d ppm: 170.6, 168.4, 160.5,
156.3, 154.2, 140.8, 134.7, 132.7, 131.2, 131.1, 129.8, 129.5,
129.2, 125.4, 124.4, 122.4, 118.0. Anal. Calcd for
C21H13BrClN3O: C, 57.49; H, 2.99; N, 9.58. Found: C,
57.64; H, 3.08; N, 9.45%.
6.3.18. 3-(4-Fluro benzylideneamino)-7-chloro-2-phenyl
quinazoline-4(3H)-one (24)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 58%; mp 224–226 C. IR (KBr,
mmax, cm
1): 3064 (CH), 1658 (C‚O), 1544 (C‚N), 1492
(C‚C), 1368 (C–N), 1214 (C–Fl), 728 (C–Cl). 1H NMR
(DMSO-d6) d ppm: 7.55–8.64 (m, 12H, Ar-H), 9.14 (s, 1H,
N‚CH). 13C NMR (DMSO-d6) d ppm: 170.0, 168.7, 165.3,
160.6, 156.5, 154.2, 140.2, 131.8, 131.2, 131.1, 130.2, 129.8,
129.2, 125.4, 122.6, 118.0, 114.8. Anal. Calcd for
C21H13ClFN3O: C, 66.76; H, 3.47; N, 11.12. Found: C,
66.64; H, 3.62; N, 11.02%.
6.3.19. 3-(3,4-Dihydroxy benzylideneamino)-7-chloro-2-phenyl
quinazoline-4(3H)-one (25)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 52%; mp 236–241 C. IR (KBr,
mmax, cm
1): 3428 (OH), 3057 (CH), 1639 (C‚O), 1515
(C‚C), 1556 (C‚N), 1494 (C‚C), 1388 (C–N), 732 (C–Cl).
1H NMR (DMSO-d6) d ppm: 7.16-8.51 (m, 11H, Ar-H), 8.91
(s, 1H, N‚CH), 9.63 (s, 2H, OH). 13C NMR (DMSO-d6) d
ppm: 170.4, 168.6, 156.4, 154.4, 152.4, 150.8, 148.2, 140.6,
132.3, 131.2, 131.1, 129.8, 129.2, 125.4, 123.5, 122.5, 118.0,
116.2, 114.2. Anal. Calcd for C21H14ClN3O3: C, 64.37; H,
3.60; N, 10.72. Found: C, 64.56; H, 3.32; N, 10.62%.
6.3.20. 3-(3-Hydroxy benzylideneamino)-7-chloro-2-phenyl
quinazoline-4(3H)-one (26)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 48%; mp 214–218 C. IR (KBr,
mmax, cm
1): 3412 (OH), 3061 (CH), 1638 (C‚O), 1532
(C‚C), 1565 (C‚N), 1489 (C‚C), 1372 (C–N), 721 (C–Cl).
1H NMR (DMSO-d6) d ppm: 7.56–8.58 (m, 12H, Ar-H),
8.96 (s, 1H, N‚CH), 9.32 (s, 1H, OH). 13C NMR (DMSO-
d6) d ppm: 170.4, 168.4, 159.4, 156.2, 154.1, 152.2, 140.7,
131.2, 131.1, 129.8, 129.2, 125.4. Anal. Calcd for
C21H14ClN3O2: C, 67.12; H, 3.75; N, 11.18. Found: C, 67.15;
H, 3.89; N, 11.24%.
6.3.21. 3-(3-Phenyl allyllidene amino)-7-chloro-2-phenyl
quinazoline-4(3H)-one (27)
This compound was prepared and puriﬁed as per the above
mentioned procedure: yield 71%; mp 283–285 C. IR (KBr)
mmax 3066 (CH), 2110 (C‚C), 1651 (C‚O), 1514 (C‚N),
1482 (C‚C), 1394 (C–N), 764 (C–Cl). 1H NMR (DMSO-d6)
d ppm: 6.95–9.32 (a set of signals, 16H, Ar-H, oleﬁnicCH‚CH and N‚CH). 13C NMR (DMSO-d6) d ppm:
170.6, 168.4, 156.2, 154.2, 140.6, 138.6, 136.2, 134.1, 131.2,
131.1, 129.8, 129.6, 129.5, 129.2, 125.9, 125.4, 122.4, 118.0.
Anal. Calcd for C23H16ClN3O: C, 71.59; H, 4.18; N, 10.89.
Found: C, 71.68; H, 4.31; N, 10.61%.Acknowledgements
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